Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene
Bea, A.M. ; Lamiquiz-Moneo, I. ; Marco-Benedí, V. ; Mateo-Gallego, R. (Universidad de Zaragoza) ; Pérez-Calahorra, S. ; Jarauta, E. (Universidad de Zaragoza) ; Martín, C. ; Cenarro, A. ; Civeira, F. (Universidad de Zaragoza)
Resumen: Background and aims: The aim of this work was to compared the effect of lipid lowering drugs among familial hypercholesterolemia (FH) subjects with a functional mutation in LDLR (LDLR FH) and FH with the p.(Leu167del) mutation in APOE.
Methods: We retrospectively selected all adults with the p.(Leu167del) mutation on lipid-lowering treatment (n = 22) attending the Lipid Unit at the Hospital Miguel Servet. Age and sex matched LDLR FH from the same Unit were randomly selected as a control group (n = 44).
Results: The mean percentage reduction in LDLc was significantly higher in the p.(Leu167del) carriers (-52.1%) than in the LDLR FH (-39.7%) (p = 0.040) when on high intensity statins. Similar differences between groups were observed in non-HDLc -49.4% and -36.4%, respectively (p = 0.030).
Conclusions: Subjects with p.(Leu167del) mutation have a higher lipid-lowering response to statins with or without ezetimibe than LDLR FH. This supports the use of genetics for a more efficient management of FH.
Idioma: Inglés
DOI: 10.1016/j.atherosclerosis.2019.01.024
Año: 2019
Publicado en: Atherosclerosis 282 (2019), 143-147
ISSN: 0021-9150
Factor impacto JCR: 3.919 (2019)
Categ. JCR: PERIPHERAL VASCULAR DISEASE rank: 16 / 65 = 0.246 (2019) - Q1 - T1
Categ. JCR: CARDIAC & CARDIOVASCULAR SYSTEMS rank: 42 / 138 = 0.304 (2019) - Q2 - T1
Factor impacto SCIMAGO: 1.515 - Cardiology and Cardiovascular Medicine (Q1)
Financiación: info:eu-repo/grantAgreement/EUR/ISCII-ERDF/A way to make Europe
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI13-02507
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI15-01983
Tipo y forma: Article (PostPrint)
Área (Departamento): Área Enfermería (Dpto. Fisiatría y Enfermería)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.
Exportado de SIDERAL (2020-07-16-08:53:13)
Visitas y descargas
Methods: We retrospectively selected all adults with the p.(Leu167del) mutation on lipid-lowering treatment (n = 22) attending the Lipid Unit at the Hospital Miguel Servet. Age and sex matched LDLR FH from the same Unit were randomly selected as a control group (n = 44).
Results: The mean percentage reduction in LDLc was significantly higher in the p.(Leu167del) carriers (-52.1%) than in the LDLR FH (-39.7%) (p = 0.040) when on high intensity statins. Similar differences between groups were observed in non-HDLc -49.4% and -36.4%, respectively (p = 0.030).
Conclusions: Subjects with p.(Leu167del) mutation have a higher lipid-lowering response to statins with or without ezetimibe than LDLR FH. This supports the use of genetics for a more efficient management of FH.
Idioma: Inglés
DOI: 10.1016/j.atherosclerosis.2019.01.024
Año: 2019
Publicado en: Atherosclerosis 282 (2019), 143-147
ISSN: 0021-9150
Factor impacto JCR: 3.919 (2019)
Categ. JCR: PERIPHERAL VASCULAR DISEASE rank: 16 / 65 = 0.246 (2019) - Q1 - T1
Categ. JCR: CARDIAC & CARDIOVASCULAR SYSTEMS rank: 42 / 138 = 0.304 (2019) - Q2 - T1
Factor impacto SCIMAGO: 1.515 - Cardiology and Cardiovascular Medicine (Q1)
Financiación: info:eu-repo/grantAgreement/EUR/ISCII-ERDF/A way to make Europe
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI13-02507
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI15-01983
Tipo y forma: Article (PostPrint)
Área (Departamento): Área Enfermería (Dpto. Fisiatría y Enfermería)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material. Exportado de SIDERAL (2020-07-16-08:53:13)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2020-02-04, last modified 2020-07-16